U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT07462442) titled 'Study of QLS5308 in Patients With Advanced Solid Tumors' on March 05.
Brief Summary: The goal of this Phase I study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of QLS5308 monotherapy in participants with Advanced Solid Tumors. This study is divided into two phases: Phase Ia is the dose escalation phase, where dose escalation of QLS5308 conducted and RP2D is explored; In the Phase Ib tumor type expansion study stage, the primary objective is to evaluate the objective response rate (ORR) of QLS5308 with advanced solid tumors.
Study Start Date: March 28
Study Type: INTERVENTIONAL
Condition: ...